Equities Research Analysts’ updated eps estimates for Friday, September 8th:

Ashmore Group (OTCMKTS:AJMPF) was upgraded by analysts at BNP Paribas from an underperform rating to a neutral rating.

Evercore ISI assumed coverage on shares of Axovant Sciences (NYSE:AXON). Evercore ISI issued an outperform rating and a $30.00 price target on the stock.

Big Lots (NYSE:BIG) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Big Lots’ second-quarter fiscal 2017 marked the seventh straight quarter of positive earnings surprise. Top line also beat the Zacks Consensus Estimate after missing the same in the trailing four quarters on account of robust performance of furniture and soft home. Following the results, management raised fiscal 2017 earnings view but remained somewhat cautious about its sales and comparable store sales performance due to softness in hard home and electronics. Management’s conservative sales guidance hurt investor sentiment, as a result the stock has underperformed the industry in a month. Big Lots now projects full year sales growth in the range of 2-2.5% versus 2-3% earlier. Meanwhile, its furniture financing programs have been consistently gaining traction. However, the challenging retail landscape, aggressive promotional strategies and waning store traffic might weigh on the performance. Of late, estimates have been falling.”

Hugo Boss AG (ETR:BOSS) was given a €65.00 ($77.38) price target by analysts at Credit Suisse Group. The firm currently has a neutral rating on the stock.

Burberry Group PLC (OTCMKTS:BURBY) was upgraded by analysts at Credit Suisse Group from a neutral rating to an outperform rating.

Cooper Companies, Inc. (The) (NYSE:COO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $270.00 price target on the stock. According to Zacks, “The Cooper Companies ended third-quarter fiscal 2017 on a solid note, beating the Zacks Consensus Estimate on both lines. The company has always seen impressive results at its CooperVision business segment. Notably, the segment banks on the platforms of MyDay, Clariti and Biofinity silicone hydrogel lenses. The CooperSurgical segment also delivered strong sales in the quarter. The company provided strong guidance for fiscal 2017. However, the dampening outlook for the CooperSurgical segment indicates looming concerns. Furthermore, intensifying competition in the contact lens space will continue to increase pricing pressure. Cooper Companies has completed the acquisition of Procornea in the recent past. This added a leading ortho-k technology to Cooper Company’s lens portfolio and marked its foray in the emerging myopia controlled markets. The company had an impressive run on the bourse over the last six months.”

CSRA (NYSE:CSRA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $37.00 price target on the stock. According to Zacks, “CSRA is the largest pure play government IT service provider. The company’s deep domain knowledge and expertise in next-generation IT services is aiding it to win new contracts on a regular basis, the most recent one being a $115 million contract from the U.S. Environmental Protection Agency (EPA). Additionally, partnerships with technology companies like Microsoft, Amazon and Oracle is a key growth driver. Moreover, anticipated improvement in federal spending is a positive for the company. However, near-term uncertainty over the renewal of Greenway contract and delay in TSA contract are headwinds. The lower recompete win rate is a concern in our view.  Notably, the company has underperformed the industry on a year-to-date basis.”

Control4 Corporation (NASDAQ:CTRL) was upgraded by analysts at Cowen and Company from a market perform rating to an outperform rating.

Deutsche Telekom AG (FRA:DTE) was given a €19.20 ($22.86) price target by analysts at UBS AG. The firm currently has a buy rating on the stock.

Fiat Chrysler Automobiles NV (BIT:F) was given a €13.40 ($15.95) price target by analysts at UBS AG. The firm currently has a neutral rating on the stock.

GlaxoSmithKline PLC (NYSE:GSK) was downgraded by analysts at Morgan Stanley from an equal rating to a weight rating.

Home Depot, Inc. (The) (NYSE:HD) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Home Depot’s spectacular past performance has helped it to surpass the industry in the past year. The company has been consistently gaining from its interconnected strategy, focus on Pro customers, and housing market recovery. These factors helped the company post a stellar second-quarter fiscal 2017 performance, which marked its highest ever quarterly sales and earnings. Notably, sales marked its 13th straight beat, while earnings retained its 5-year long trend of positive surprise. Results were driven by solid growth across all regions, both in stores and online. Also, Pro category sales continued to outperform, driven by constant efforts to enrich customers’ experiences. The sturdy first half and expectations of improved home prices encouraged the company to raise its fiscal 2017 view. However, gross margin remained plateaued, and is likely to fall 10 bps in fiscal 2017. Also, competition from online retailers may impact results.”

Janney Montgomery Scott started coverage on shares of Highwoods Properties (NYSE:HIW). Janney Montgomery Scott issued a neutral rating on the stock.

Evercore ISI initiated coverage on shares of HubSpot (NYSE:HUBS). Evercore ISI issued an outperform rating and a $90.00 price target on the stock.

Iberdrola SA (MCE:IBE) was given a €6.40 ($7.62) price target by analysts at UBS AG. The firm currently has a neutral rating on the stock.

Keryx Biopharmaceuticals (NASDAQ:KERX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Keryx posted wider than expected loss in the second quarter of 2017 but sales exceeded expectations.  With Auryxia being the only approved product in Keryx’s portfolio, the company is entirely dependent on Auryxia for growth. Auryxia faces stiff competition in the U.S. from existing players, apart from over-the-counter drugs like some calcium carbonate and metal-based products. Apart from competition, Keryx may face strong pricing pressure for Auryxia. However, the company is making efforts to expand the label of Auryxia. The  FDA accepted for review the supplemental New Drug Application (sNDA) for Auryxia tablets for the iron-deficiency anemia (IDA) indication and has set the Prescription Drug User Fee Act (PDUFA) target action date on Nov 6, 2017. A potential approval should increase sales. Shares of the company have outperformed the industry year to date.”

CarMax (NYSE:KMX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $77.00 target price on the stock. According to Zacks, “CarMax is one of the strongest operators in the used-car market, which helps it occupy a significant market share, among its peers. The company is also following an aggressive store expansion initiative to strengthen its presence and cater to a larger customer group. Moreover, it enhances shareholders value by undertaking frequent share buyback programs. Also, in the last three months, its shares have outperformed the industry it belongs to.”

Lanxess AG (ETR:LXS) had its buy rating reaffirmed by analysts at DZ Bank AG.

Verifone Systems (NYSE:PAY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “VeriFone’s third-quarter fiscal 2017 results were unimpressive. Earnings were in line with the Zacks Consensus Estimate but declined on a year-over-year basis due to weak top-line growth. The decline can be attributed to sluggishness in the Asia-Pacific and North America regions. This was partially offset by strong revenue growth in Latin America and Europe, Middle East and Africa (EMEA). Management expects this weakness to continue, which along with the taxi business divestiture, compelled it to lower fiscal 2017 guidance. Notably, the stock has underperformed the industry on a year-to-date basis. However, the company believes that strength in retail and SMB will help the North America segment revenues to recover going forward. We believe that the company's strong product portfolio that now includes the likes of Carbon 8 and Engage will help in expanding customer base in the long haul.”

PEUGEOT SA EUR1 (OTCMKTS:PEUGF) was downgraded by analysts at BNP Paribas from a neutral rating to an underperform rating.

Synergy Pharmaceuticals (NASDAQ:SGYP) had its price target reduced by Oppenheimer Holdings, Inc. from $9.00 to $6.00. They currently have an outperform rating on the stock.

Schaeffler AG (FRA:SHA) was given a €10.00 ($11.90) target price by analysts at UBS AG. The firm currently has a sell rating on the stock.

Yum! Brands (NYSE:YUM) had its target price boosted by Oppenheimer Holdings, Inc. from $80.00 to $85.00. Oppenheimer Holdings, Inc. currently has an outperform rating on the stock.

Zpg Plc (LON:ZPLA) had its target price increased by Deutsche Bank AG from GBX 325 ($4.20) to GBX 340 ($4.39). Deutsche Bank AG currently has a hold rating on the stock.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.